evidence/gaps
Cochrane · systematic review · CD007933

Genital ulcer disease treatment for reducing sexual acquisition of HIV

Mutua, FM, M'Imunya, JM, Wiysonge, CS · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Azithromycin (single‐ or two‐dose) compared to penicillin for patients with syphilis

Population: patients with syphilis
2 questions
OutcomeEffectEvidenceStatus / GRADE
HIV seroconversion ‐ penicillin vs single‐dose azithromycin
Azithromycin (single‐ or two‐dose) vs penicillin
no estimate extracted1 study · 19 participantsVery low
Downgraded: risk of bias, imprecision
HIV seroconversion ‐ penicillin vs two‐dose azithromycin
Azithromycin (single‐ or two‐dose) vs penicillin
no estimate extracted1 study · 22 participantsVery low
Downgraded: risk of bias, imprecision

Fleroxacin 200 mg or TMP‐SMZ compared to fleroxacin 400 mg for patients with chancroid

Population: patients with chancroid
2 questions
OutcomeEffectEvidenceStatus / GRADE
HIV seroconversion ‐ fleroxacin 400 mg vs fleroxacin 200 mg
Fleroxacin 200 mg or TMP‐SMZ vs fleroxacin 400 mg
RR 3 [0.29, 30.69]1 study · 45 participantsVery low
Downgraded: risk of bias, imprecision
HIV seroconversion ‐ fleroxacin 400 mg vs TMP‐SMZ
Fleroxacin 200 mg or TMP‐SMZ vs fleroxacin 400 mg
RR 0.33 [0.04, 3.09]1 study · 98 participantsVery low
Downgraded: risk of bias, imprecision